- 11 September 2019
- 2 min read
Immunotherapy drug boosts lung cancer survival – study
SubscribeNivolumab helps the patient’s own immune system find and destroy cancer cells as they spread.

Game-changing drug for lung cancer
Lung cancer patients taking a game-changing drug are five times more likely to be alive after five years than those on chemotherapy, research suggests.
The immunotherapy drug nivolumab (Opdivo), which is used for several cancers, works by blocking a protein that stops the immune system attacking cancer cells.
The drug helps the patient’s own immune system find and destroy cancer cells as they spread.
Extending survival
Now, new research presented at the World Conference on Lung Cancer in Barcelona shows the drug can have a powerful effect in extending survival for people with advanced lung cancer who have few treatment options.
Research on 854 patients, presented by Dr Scott Gettinger of Yale Comprehensive Cancer Centre in the US, showed that those on the drug were five times more likely to still be alive after five years than those on conventional chemotherapy (docetaxel).
Five-year survival rates were 13.4% for people on the drug compared to 2.6% for those on chemotherapy.
The overall survival benefit with nivolumab compared with docetaxel was observed across sub groups of patients, including those who were previously thought to derive lesser benefit from the drug.
About this contributor
Nurses.co.uk editorial team
Bringing you a daily update of nursing, NHS, health and social care news from around the UK.
More by this contributorWant to get involved in the discussion?
Log In Subscribe to comment